TM9SF4

Across TCGA pan-cancer cohorts, TM9SF4 RNA is linked to patient survival in 26 of 34 cancer types, making it the most broadly survival-associated TM9SF4 data layer compared with 5 for mutation status and 3 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher TM9SF4 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated TM9SF4 expression acts as an unfavorable survival marker, although some lineages such as READ and UCS show a favorable association.

LIHC, BLCA, and UVM are the cancer types where TM9SF4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	All	0.471	0.613	<.001	86	view →
BLCA	DFS	Quartile	All	0.211	0.503	<.001	73	view →
UVM	DFS	Tertile	All	0.428	0.804	<.001	64	view →
KIRP	DFS	Quartile	All	0.852	0.989	<.001	51	view →
MESO	DFS	Quartile	III,IV	0.305	0.599	.010	35	view →
LGG	OS	Median	All	0.747	0.880	<.001	30	view →
SARC	OS	Tertile	All	0.415	0.625	.001	29	view →
ACC	DFS	Tertile	All	0.471	0.783	.003	27	view →
READ	DFS	Median	IV	0.823	0.370	.003	26	view →
UCEC	DFS	Tertile	All	0.774	0.882	.001	24	view →
UCS	DFS	Tertile	IV	0.832	0.239	.024	24	view →
KICH	DFS	Quartile	III,IV	0.317	1.000	.022	16	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 26 lineages.

TM9SF4–LIHC (DFS)

Open the LIHC breakdown →